Medical Device News Magazine

Bio-Rad Launches Celselect Slides 2.0 to Advance Rare Cell and Circulating Tumor Cell Enrichment for Cancer Research

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of Celselect Slides 2.0 to enhance rare cell and circulating tumor cell (CTC) capture. Compatible with Bio-Rad’s Genesis Cell Isolation System, the latest version of Celselect Slides enables the processing of greater volumes of liquid biopsy samples and offers the ability to capture and recover a greater number of CTCs for enumeration or use in downstream applications.

The Genesis Cell Isolation System provides researchers with unbiased size-based microfluidic cell selection to gently and efficiently capture a wide range of CTCs and other rare cells from liquid biopsy samples such as blood in one benchtop solution. The latest version of Celselect Slides allows researchers to load 2.5x more sample per slide compared to Celselect Slides 1.0, increasing the sample volume from 4 ml to 10 ml. The number of microchambers in which CTCs are captured has also increased, from 56,400 in the version 1.0 slides to 140,800 in the version 2.0 slides. The Genesis System’s two-bay design accepts two Celselect Slides that can be run independently, now permitting a total volume of 20 ml of sample to be processed at one time. Bio-Rad’s new slide design is also compatible with full standard blood tube runs (~8 ml), allowing seamless integration into researchers’ existing workflows.

The increased volume of liquid biopsy sample accepted by the Genesis Cell Isolation System will allow researchers to process a larger amount of sample in a single run, improving the efficiency of CTC capture. This will increase the number of viable CTCs captured for immunofluorescence applications such as enumeration and identification of various CTC types, for downstream analyses such as next-generation sequencing or Droplet Digital™ PCR, or for sub-cultivation

“CTCs are rare — as low as only 1–10 can be found per milliliter of blood — however, CTC enumeration and analysis offers valuable insight into tumor heterogeneity and disease progression,” said Stephen Kulisch, Vice President of Marketing for Bio-Rad’s Digital Biology Group. “Building on the capabilities of Celselect Slides 1.0, we’re continuing to improve the efficiency of rare CTC enrichment, enumeration, and recovery to accelerate cancer research workflows. This launch reflects the expansion of our technological capabilities and our commitment to bringing novel solutions to researchers to improve our understanding of cancer and inform research programs.”

Medical Device News Magazine
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”